AU2002226211A1 - Individualized anti-cancer antibodies - Google Patents

Individualized anti-cancer antibodies

Info

Publication number
AU2002226211A1
AU2002226211A1 AU2002226211A AU2002226211A AU2002226211A1 AU 2002226211 A1 AU2002226211 A1 AU 2002226211A1 AU 2002226211 A AU2002226211 A AU 2002226211A AU 2002226211 A AU2002226211 A AU 2002226211A AU 2002226211 A1 AU2002226211 A1 AU 2002226211A1
Authority
AU
Australia
Prior art keywords
cancer antibodies
individualized anti
individualized
antibodies
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226211A
Inventor
Miyoko Takahashi
David S. F. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arius Research Inc
Original Assignee
Arius Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Research Inc filed Critical Arius Research Inc
Publication of AU2002226211A1 publication Critical patent/AU2002226211A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002226211A 2001-12-21 2001-12-21 Individualized anti-cancer antibodies Abandoned AU2002226211A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2001/001838 WO2003055515A1 (en) 2001-12-21 2001-12-21 Individualized anti-cancer antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004248865A Division AU2004248865B2 (en) 2001-12-21 2004-06-08 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
AU2002226211A1 true AU2002226211A1 (en) 2003-07-15

Family

ID=4143189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226211A Abandoned AU2002226211A1 (en) 2001-12-21 2001-12-21 Individualized anti-cancer antibodies

Country Status (5)

Country Link
EP (1) EP1455819A1 (en)
JP (1) JP2005518393A (en)
AU (1) AU2002226211A1 (en)
CA (1) CA2471206A1 (en)
WO (1) WO2003055515A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248865B2 (en) * 2001-12-21 2011-07-21 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
WO2007123791A2 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2692823A1 (en) * 2007-07-16 2009-01-22 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
KR20100021659A (en) * 2007-07-16 2010-02-25 에프. 호프만-라 로슈 아게 An anti-cancer cytotoxic monoclonal antibody
AU2008278227A1 (en) * 2007-07-16 2009-01-22 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
US20090068100A1 (en) * 2007-08-27 2009-03-12 Young David S F Cancerous disease modifying antibodies
US20090068099A1 (en) * 2007-09-10 2009-03-12 Young David S F Cancerous disease modifying antibodies
US20090104115A1 (en) * 2007-10-03 2009-04-23 Young David S F Cancerous disease modifying antibodies
US20090191120A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191119A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
WO2009124381A1 (en) * 2008-04-10 2009-10-15 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
JP2011520923A (en) * 2008-05-19 2011-07-21 武田薬品工業株式会社 Cytotoxic anti-cancer monoclonal antibody
WO2009140755A1 (en) * 2008-05-19 2009-11-26 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
US10393733B2 (en) 2012-09-19 2019-08-27 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
EP3047276B1 (en) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
CA2983022C (en) 2015-04-27 2023-03-07 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69534347T2 (en) * 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Libraries of polyclonal antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248865B2 (en) * 2001-12-21 2011-07-21 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
EP1455819A1 (en) 2004-09-15
WO2003055515A1 (en) 2003-07-10
CA2471206A1 (en) 2003-07-10
JP2005518393A (en) 2005-06-23

Similar Documents

Publication Publication Date Title
AU2002226211A1 (en) Individualized anti-cancer antibodies
AU2002256895A1 (en) Anti-TRAIL-R antibodies
EP2363404B8 (en) PSMA antibodies
AU2003217912A1 (en) Antibody optimization
AU2003219277A1 (en) Intracellular antibodies
EP2270052B8 (en) Antibodies to OPGL
EP1432444A4 (en) Anti-a-beta antibodies
HK1074206A1 (en) Anti-trail-r antibodies
AU2003264009A1 (en) Humanized rabbit antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
AUPR395801A0 (en) Antibodies against cancer
AU2002303384A1 (en) Epitope-captured antibody display
AU2002365649A1 (en) Anti-dota antibody
AU2003239197A1 (en) Novel stable anti-cd22 antibodies
AU2002307438A1 (en) Cancer-testis antigens
AUPR546801A0 (en) Recombinant antibodies
AU2002305903A1 (en) Carbohydrate-associated proteins
AU2003275834A1 (en) ANTIBODIES THAT BIND alphaE INTEGRIN
AU2002221132A1 (en) Novel antibody
AU2002324727A1 (en) Mammalian relaxin receptors
WO2002077001A9 (en) Novel receptors
AU2002357850A1 (en) Neurotransmission-associated proteins
AU2001295042A1 (en) Anti-stilbene antibodies
AU2002231806A1 (en) H. influenzae antigen basb213
AU2002239951A1 (en) Hydrocarbon sensor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase